Drug delivery devices help in delivering the drugs which are beneficial for the targeted population to recover faster. In addition, a rising number of ca...
J-Brain Cargo®, which is a JCR proprietary technology, allows the delivery of biotherapeutics into the central nervous system (“CNS”) via a...
In the feasibility study, scientists at the Milan site will focus on identifying proof of concept and viability for developing a prototype for an exosome-b...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Seagen Inc. (Nasdaq: SGEN) announced the U.S. Food and Drug Administrati...
PHC is a subsidiary of PHC Group*1, a global healthcare company that develops, manufactures, sells, and services solutions across the business domains of d...
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assay...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has entered into an agreement ("the Agr...
Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., "Cellusion") announced that our research collaborator, Dr. Shigeto Shimmura, Professor of Fujita Health Univer...
ncyte (Nasdaq:INCY) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fi...
Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from Astellas Acquiring leading global echinocandin, one of three...
© 2024 Biopharma Boardroom. All Rights Reserved.
